NCT02208375 - mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Biotech Hunter

Enrollment

159

Participants

Timeline

Start Date

November 11, 2014

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial AdenocarcinomaEstrogen Receptor NegativeHER2/Neu NegativeHigh Grade Ovarian Serous AdenocarcinomaProgesterone Receptor NegativeRecurrent Breast CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus CarcinomaStage III Uterine Corpus Cancer AJCC v7Stage IV Breast Cancer AJCC v6 and v7Stage IV Uterine Corpus Cancer AJCC v7Triple-Negative Breast Carcinoma

Interventions

DRUG

Capivasertib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Olaparib

Given PO

OTHER

Pharmacological Study

Correlative studies

DRUG

Vistusertib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER